Association of Galectin-9 Soluble Immune Checkpoint with Clinical Prognostic Markers in Patients with Chronic Lymphocytic Leukemia
Aviwe Ntsethe, Phiwayinkosi Vusi Dludla, Bongani Brian Nkambule · 2025
Read Association of Galectin-9 Soluble Immune Checkpoint with Clinical Prognostic Markers in Patients with Chronic Lymphocytic Leukemia by Aviwe Ntsethe, Phiwayinkosi Vusi Dludla, Bongani Brian Nkambule (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12785695.txt.
Description
Aviwe Ntsethe, Phiwayinkosi Dludla, and Bongani Nkambule profiled soluble immune checkpoints in chronic lymphocytic leukemia blood, in a 2025 study. The disease swings widely between patients, and bead assays promise cheap monitoring if any marker truly tracks prognosis. The team measured six checkpoints, including galectin-9, plus a standard risk protein, and lined them up against staging, gene tests, and a composite index.
Five checkpoints ran far higher in patients than controls. Galectin-9 rose in step with the standard risk protein, the study's headline link. The authors propose it as a candidate prognostic marker for a disease that needs better ones. Validation in bigger cohorts comes next.
Catalog record
| CREATOR | Aviwe Ntsethe, Phiwayinkosi Vusi Dludla, Bongani Brian Nkambule |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |